Cargando…

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosquera Orgueira, Adrián, Díaz Arías, Jose Ángel, Serrano Martín, Rocio, Portela Piñeiro, Victor, Cid López, Miguel, Peleteiro Raíndo, Andrés, Bao Pérez, Laura, González Pérez, Marta Sonia, Pérez Encinas, Manuel Mateo, Fraga Rodríguez, Máximo Francisco, Vallejo Llamas, Juan Carlos, Bello López, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/
https://www.ncbi.nlm.nih.gov/pubmed/37188190
http://dx.doi.org/10.3389/fonc.2023.1157646
_version_ 1785040280870715392
author Mosquera Orgueira, Adrián
Díaz Arías, Jose Ángel
Serrano Martín, Rocio
Portela Piñeiro, Victor
Cid López, Miguel
Peleteiro Raíndo, Andrés
Bao Pérez, Laura
González Pérez, Marta Sonia
Pérez Encinas, Manuel Mateo
Fraga Rodríguez, Máximo Francisco
Vallejo Llamas, Juan Carlos
Bello López, José Luis
author_facet Mosquera Orgueira, Adrián
Díaz Arías, Jose Ángel
Serrano Martín, Rocio
Portela Piñeiro, Victor
Cid López, Miguel
Peleteiro Raíndo, Andrés
Bao Pérez, Laura
González Pérez, Marta Sonia
Pérez Encinas, Manuel Mateo
Fraga Rodríguez, Máximo Francisco
Vallejo Llamas, Juan Carlos
Bello López, José Luis
author_sort Mosquera Orgueira, Adrián
collection PubMed
description Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.
format Online
Article
Text
id pubmed-10175759
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101757592023-05-13 A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma Mosquera Orgueira, Adrián Díaz Arías, Jose Ángel Serrano Martín, Rocio Portela Piñeiro, Victor Cid López, Miguel Peleteiro Raíndo, Andrés Bao Pérez, Laura González Pérez, Marta Sonia Pérez Encinas, Manuel Mateo Fraga Rodríguez, Máximo Francisco Vallejo Llamas, Juan Carlos Bello López, José Luis Front Oncol Oncology Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups. Frontiers Media S.A. 2023-04-28 /pmc/articles/PMC10175759/ /pubmed/37188190 http://dx.doi.org/10.3389/fonc.2023.1157646 Text en Copyright © 2023 Mosquera Orgueira, Díaz Arías, Serrano Martín, Portela Piñeiro, Cid López, Peleteiro Raíndo, Bao Pérez, González Pérez, Pérez Encinas, Fraga Rodríguez, Vallejo Llamas and Bello López https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mosquera Orgueira, Adrián
Díaz Arías, Jose Ángel
Serrano Martín, Rocio
Portela Piñeiro, Victor
Cid López, Miguel
Peleteiro Raíndo, Andrés
Bao Pérez, Laura
González Pérez, Marta Sonia
Pérez Encinas, Manuel Mateo
Fraga Rodríguez, Máximo Francisco
Vallejo Llamas, Juan Carlos
Bello López, José Luis
A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_full A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_fullStr A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_full_unstemmed A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_short A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_sort prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large b-cell lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/
https://www.ncbi.nlm.nih.gov/pubmed/37188190
http://dx.doi.org/10.3389/fonc.2023.1157646
work_keys_str_mv AT mosqueraorgueiraadrian aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT diazariasjoseangel aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT serranomartinrocio aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT portelapineirovictor aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT cidlopezmiguel aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT peleteiroraindoandres aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT baoperezlaura aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT gonzalezperezmartasonia aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT perezencinasmanuelmateo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT fragarodriguezmaximofrancisco aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT vallejollamasjuancarlos aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT bellolopezjoseluis aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT mosqueraorgueiraadrian prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT diazariasjoseangel prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT serranomartinrocio prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT portelapineirovictor prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT cidlopezmiguel prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT peleteiroraindoandres prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT baoperezlaura prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT gonzalezperezmartasonia prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT perezencinasmanuelmateo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT fragarodriguezmaximofrancisco prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT vallejollamasjuancarlos prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT bellolopezjoseluis prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma